logo
Share SHARE
FONT-SIZE Plus   Neg

Steven Simms Appointed As Chief EXecutive Officer At Colfax Corp- Quick Facts

Colfax Corporation (CFX) Monday announced that Steven E. Simms has been appointed as the Chief Executive Officer of the company with immediate effect.

Steven Simms will succeed Clay Kiefaber, who has been named as the new CEO of Colfax's ESAB business, which was recently acquired by the company in the Charter International transaction.

Simms has more than 20 years of senior executive experience at leading global corporations. He spent 11 years from 1996 to 2007 in increasingly senior positions at Danaher, a Fortune 200 science and technology leader that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers.

Mitchell P. Rales, Chairman of the Board of Colfax, said, "Steve Simms is a world-class executive, and we are thrilled that he has agreed to join Colfax on a full-time basis at this critical stage in the Company's growth and strategic development. Steve has deep international, strategic and operational experience, as well as a strong track record of successfully integrating acquisitions and increasing profitability, making him the ideal leader for Colfax at this inflection point in the company's size and complexity. .."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The European Union's executive arm has ordered the Irish government to recover up to 13 billion euros, or $14.5 billion, in taxes from Apple Inc. The European Commission said it has concluded that Ireland granted the U.S. tech giant undue tax benefits of up to 13 billion euros, which is illegal under EU state aid rules. Shares of Apple are down 1 percent in pre-market activity. Abercrombie & Fitch Co. (ANF) reported Tuesday a wider year-over-year net loss for the second-quarter, hurt by a impairment charge. Net sales for the quarter were down 4%, with comparable sales declined 4%. Quarterly loss was wider than their expectations, but revenues beat their' estimates. The performance of Biotech stocks thus far this month is nothing to write home about, if we were to look at it from the standpoint of the movement of the NYSE Arca Biotechnology Index. A peek at what transpired on the FDA front in August and a preview of what September holds in store for us look pertinent.
comments powered by Disqus
Follow RTT